1. High/positive expression of ERCC1 predicts poor treatment response and survival prognosis in nasopharyngeal carcinoma
- Author
-
Guangyuan Hu, Lin Yang, Lei Zhou, Jing Wang, and Wenjie Wei
- Subjects
Oncology ,medicine.medical_specialty ,Proportional hazards model ,business.industry ,Hazard ratio ,General Medicine ,Publication bias ,Odds ratio ,medicine.disease ,Confidence interval ,03 medical and health sciences ,0302 clinical medicine ,Nasopharyngeal carcinoma ,030220 oncology & carcinogenesis ,Meta-analysis ,Internal medicine ,medicine ,030212 general & internal medicine ,ERCC1 ,business - Abstract
BACKGROUND Excision repair cross-complementation group 1 (ERCC1) protein is a member of the nucleotide excision repair (NER) system, which plays an important role in DNA damage repair. Recently, its predictive and prognostic value in nasopharyngeal carcinoma (NPC) has been investigated by several studies. However, their results remain controversial. OBJECTIVES In an attempt to address this issue, we conducted the present comprehensive meta-analysis. DATA SOURCES Studies published until November 2017 were searched. Finally, total 21 literatures involving 22 cohorts and 2921 NPC patients fulfilled the inclusion criteria. RESULTS The pooled results showed that high/positive expression of ERCC1 predicted poor objective response rate (ORR) [odds ratio (OR) = 2.83; 95% confidence interval (CI) = 2.11-3.80; P
- Published
- 2019
- Full Text
- View/download PDF